Literature DB >> 11438451

Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC.

H Lassus1, R Salovaara, L A Aaltonen, R Butzow.   

Abstract

The distal half of chromosome arm 18q is frequently lost in ovarian carcinoma. To define the putative tumor suppressor locus/loci more precisely we performed allelic analysis with 27 polymorphic microsatellite markers located at 18q12.3-q23 in 64 serous and 9 mucinous ovarian carcinomas. Fifty-nine percent of the serous carcinomas, but only one (11%) of mucinous carcinomas, showed allelic loss at one or more loci (P = 0.018). In serous carcinomas, deletions were found to be associated with tumor grade and poor survival. The highest frequency of losses was detected at the distal part, 18q22-q23. Two minimal common regions of loss (MCRL) were identified at this region: MCRL1 between D18S465 and D18S61 at 18q22 (3.9 cM) and MCRL2 between D18S462 and D18S70 at 18q23 (5.8 cM). At 18q21.1, proximal to the MCRLs, there are three candidate tumor suppressor genes: SMAD4 (DPC4), SMAD2, and DCC. Their protein expression was studied by immunohistochemistry in normal ovarian tissue and serous carcinomas. Lost or very weak expression of SMAD4, SMAD2 and DCC was found in 28, 28, and 30% of serous carcinomas, respectively. Comparison of allelic loss and protein expression status indicated that none of these genes alone could be the target for the frequent allelic loss at 18q21.1. Together, these genes may account for a substantial proportion of the events, but not all of them. Thus, we propose that the frequent allelic loss at 18q is because of the effect of multiple genes, and there is at least one as yet unidentified tumor suppressor gene at 18q residing distal to SMAD4, SMAD2, and DCC involved in serous ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438451      PMCID: PMC1850432          DOI: 10.1016/S0002-9440(10)61670-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus.

Authors:  G Chenevix-Trench; J Leary; J Kerr; J Michel; R Kefford; T Hurst; P G Parsons; M Friedlander; S K Khoo
Journal:  Oncogene       Date:  1992-06       Impact factor: 9.867

2.  Comparison of serous and mucinous ovarian carcinomas: distinct pattern of allelic loss at distal 8p and expression of transcription factor GATA-4.

Authors:  H Lassus; M P Laitinen; M Anttonen; M Heikinheimo; L A Aaltonen; O Ritvos; R Butzow
Journal:  Lab Invest       Date:  2001-04       Impact factor: 5.662

3.  Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Authors:  R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity.

Authors:  I Zborovskaya; A Gasparian; A Karseladze; I Elcheva; E Trofimova; K Driouch; M Trassard; A Tatosyan; R Lidereau
Journal:  Int J Cancer       Date:  1999-09-09       Impact factor: 7.396

5.  Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway.

Authors:  J Xu; L Attisano
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

6.  Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.

Authors:  D Wang; T Kanuma; H Mizunuma; F Takama; Y Ibuki; N Wake; A Mogi; Y Shitara; S Takenoshita
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

7.  An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer.

Authors:  S Suzuki; D H Moore; D G Ginzinger; T E Godfrey; J Barclay; B Powell; D Pinkel; C Zaloudek; K Lu; G Mills; A Berchuck; J W Gray
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

8.  K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.

Authors:  T Enomoto; C M Weghorst; M Inoue; O Tanizawa; J M Rice
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

9.  Allelotype of human ovarian cancer.

Authors:  T Sato; H Saito; R Morita; S Koi; J H Lee; Y Nakamura
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

10.  Identification of a chromosome 18q gene that is altered in colorectal cancers.

Authors:  E R Fearon; K R Cho; J M Nigro; S E Kern; J W Simons; J M Ruppert; S R Hamilton; A C Preisinger; G Thomas; K W Kinzler
Journal:  Science       Date:  1990-01-05       Impact factor: 47.728

View more
  9 in total

1.  Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques.

Authors:  Marilanda Ferreira Bellini; Ana Elizabete Silva; Marileila Varella-Garcia
Journal:  Genet Mol Biol       Date:  2010-06-01       Impact factor: 1.771

2.  Allelotyping for loss of heterozygosity on chromosome 18 in gastric cancer.

Authors:  Jing-Cui Yu; Kai-Lai Sun; Buo Liu; Song-Bin Fu
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

3.  A sparse Ising model with covariates.

Authors:  Jie Cheng; Elizaveta Levina; Pei Wang; Ji Zhu
Journal:  Biometrics       Date:  2014-08-05       Impact factor: 2.571

4.  Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells.

Authors:  Liu Meimei; Li Peiling; Li Baoxin; Li Changmin; Zhuang Rujin; Hu Chunjie
Journal:  Med Oncol       Date:  2010-01-07       Impact factor: 3.064

5.  Activin induces x-zone apoptosis that inhibits luteinizing hormone-dependent adrenocortical tumor formation in inhibin-deficient mice.

Authors:  Felix Beuschlein; Brendan D Looyenga; Stephanie E Bleasdale; Chris Mutch; David L Bavers; Albert F Parlow; John H Nilson; Gary D Hammer
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

6.  Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.

Authors:  C Salek; L Benesova; M Zavoral; V Nosek; L Kasperova; M Ryska; R Strnad; E Traboulsi; M Minarik
Journal:  World J Gastroenterol       Date:  2007-07-21       Impact factor: 5.742

7.  Netrin-1 overexpression is predictive of ovarian malignancies.

Authors:  Anastasios D Papanastasiou; Georgios Pampalakis; Dionyssios Katsaros; Georgia Sotiropoulou
Journal:  Oncotarget       Date:  2011-05

8.  Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.

Authors:  Alicia A Tone; Melissa K McConechy; Winnie Yang; Jiarui Ding; Stephen Yip; Esther Kong; Kwong-Kwok Wong; David M Gershenson; Helen Mackay; Sohrab Shah; Blake Gilks; Anna V Tinker; Blaise Clarke; Jessica N McAlpine; David Huntsman
Journal:  BMC Cancer       Date:  2014-12-18       Impact factor: 4.430

9.  Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.

Authors:  C A Barton; B S Gloss; W Qu; A L Statham; N F Hacker; R L Sutherland; S J Clark; P M O'Brien
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.